Left ventricular speckle tracking echocardiographic evaluation before and after TAVI.

IF 3.2 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Echo Research and Practice Pub Date : 2020-09-01 DOI:10.1530/ERP-20-0009

Vasiliki Tsampasian, Vasileios Panoulas, Richard J Jabbour, Neil Ruparelia, Iqbal S Malik, Nearchos Hadjiloizou, Angela Frame, Sayan Sen, Nilesh Sutaria, Ghada W Mikhail, Petros Nihoyannopoulos

{"title":"Left ventricular speckle tracking echocardiographic evaluation before and after TAVI.","authors":"Vasiliki Tsampasian, Vasileios Panoulas, Richard J Jabbour, Neil Ruparelia, Iqbal S Malik, Nearchos Hadjiloizou, Angela Frame, Sayan Sen, Nilesh Sutaria, Ghada W Mikhail, Petros Nihoyannopoulos","doi":"10.1530/ERP-20-0009","DOIUrl":null,"url":null,"abstract":"Aims: To assess left ventricular (LV) function before and after transcatheter aortic valve implantation (TAVI) using conventional echocardiographic parameters and global longitudinal LV strain (GLS) and compare outcomes between Edwards S3 and Evolut R valves.Methods and results: Data were collected for consecutive patients undergoing TAVI at Hammersmith hospital between 2015 and 2018. Of the 303 patients, those with coronary artery disease and atrial fibrillation were excluded leading to a total of 85 patients, which constituted our study group. The mean follow-up was 49 ± 39 days. In total, 60% of patients were treated with Edwards S3 and 40% Evolut R. TAVI resulted in an early improvement of GLS (-13.96 to -15.25%, P = 0.01) but not ejection fraction (EF) (47.6 to 50.1%, P = 0.09). LV mass also improved, especially in patients with marked baseline LV hypertrophy (P < 0.001). There were no appreciable differences of LV function improvement and overall LV remodelling after TAVI between the two types of valves used (P = 0.14).Conclusions: TAVI results in reverse remodelling and improvement of GLS, especially in patients with impaired baseline LV function. There were no differences in the extent of LV function improvement between Edwards S3 and Evolut R valves but there was a greater incidence of aortic regurgitation with Evolut R.","PeriodicalId":45749,"journal":{"name":"Echo Research and Practice","volume":null,"pages":null},"PeriodicalIF":3.2000,"publicationDate":"2020-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/6b/b8/ERP-20-0009.PMC7487179.pdf","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Echo Research and Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1530/ERP-20-0009","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 2

Abstract

Aims: To assess left ventricular (LV) function before and after transcatheter aortic valve implantation (TAVI) using conventional echocardiographic parameters and global longitudinal LV strain (GLS) and compare outcomes between Edwards S3 and Evolut R valves.

Methods and results: Data were collected for consecutive patients undergoing TAVI at Hammersmith hospital between 2015 and 2018. Of the 303 patients, those with coronary artery disease and atrial fibrillation were excluded leading to a total of 85 patients, which constituted our study group. The mean follow-up was 49 ± 39 days. In total, 60% of patients were treated with Edwards S3 and 40% Evolut R. TAVI resulted in an early improvement of GLS (-13.96 to -15.25%, P = 0.01) but not ejection fraction (EF) (47.6 to 50.1%, P = 0.09). LV mass also improved, especially in patients with marked baseline LV hypertrophy (P < 0.001). There were no appreciable differences of LV function improvement and overall LV remodelling after TAVI between the two types of valves used (P = 0.14).

Conclusions: TAVI results in reverse remodelling and improvement of GLS, especially in patients with impaired baseline LV function. There were no differences in the extent of LV function improvement between Edwards S3 and Evolut R valves but there was a greater incidence of aortic regurgitation with Evolut R.

Abstract Image

查看原文本刊更多论文

TAVI前后左心室斑点跟踪超声心动图评价。

目的:利用常规超声心动图参数和左室纵向应变(GLS)评价经导管主动脉瓣植入术(TAVI)前后左室功能，并比较Edwards S3和Evolut R瓣膜的效果。方法与结果:收集2015年至2018年在Hammersmith医院连续接受TAVI的患者的数据。303例患者中，排除冠状动脉疾病和心房颤动患者，共85例患者构成我们的研究组。平均随访时间为49±39天。总的来说，60%的患者接受Edwards S3治疗，40%的患者接受Evolut r治疗。TAVI导致GLS的早期改善(-13.96 ~ -15.25%，P = 0.01)，但没有射血分数(EF) (47.6 ~ 50.1%， P = 0.09)。左室质量也有所改善，特别是基线左室肥厚明显的患者(P < 0.001)。两种瓣膜在TAVI后左室功能改善和整体左室重构方面无明显差异(P = 0.14)。结论:TAVI可导致GLS的反向重构和改善，特别是在基线左室功能受损的患者中。Edwards S3和Evolut R瓣膜在左室功能改善程度上没有差异，但Evolut R瓣膜的主动脉反流发生率更高。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Echo Research and Practice CARDIAC & CARDIOVASCULAR SYSTEMS-

CiteScore

6.70

自引率

12.70%

发文量

审稿时长

8 weeks

期刊介绍： Echo Research and Practice aims to be the premier international journal for physicians, sonographers, nurses and other allied health professionals practising echocardiography and other cardiac imaging modalities. This open-access journal publishes quality clinical and basic research, reviews, videos, education materials and selected high-interest case reports and videos across all echocardiography modalities and disciplines, including paediatrics, anaesthetics, general practice, acute medicine and intensive care. Multi-modality studies primarily featuring the use of cardiac ultrasound in clinical practice, in association with Cardiac Computed Tomography, Cardiovascular Magnetic Resonance or Nuclear Cardiology are of interest. Topics include, but are not limited to: 2D echocardiography 3D echocardiography Comparative imaging techniques – CCT, CMR and Nuclear Cardiology Congenital heart disease, including foetal echocardiography Contrast echocardiography Critical care echocardiography Deformation imaging Doppler echocardiography Interventional echocardiography Intracardiac echocardiography Intraoperative echocardiography Prosthetic valves Stress echocardiography Technical innovations Transoesophageal echocardiography Valve disease.